The effect of thyrotrophin releasing hormone versus placebo in combination with basic imipramine therapy of depressive patients

20 female and 10 male patients with a retarded-depressive syndrome received imipramine (3 X 50 mg/day) for 20 days. In a double blind study oral thyrotrophin releasing hormone (TRH) (2 X 40 mg/day) and placebo, respectively, were added for the first 2 weeks. The patients were rated with the Hamiltion-depression scale and a selfrating depression scale. But the statistical evaluation showed no difference between the imipramine/TRH and the imipramine/placebo group.